Find Funding Opportunities

Find Funding Opportunities

Returning 29 results
Filter By:

Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)

PAR
Friday, January 3, 2020
Sunday, January 8, 2023
R01
PAR-20-055

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)

PAR
Friday, January 3, 2020
Sunday, January 8, 2023
R21
PAR-20-082

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)

RFA
Thursday, January 2, 2020
Tuesday, October 4, 2022
R01
RFA-NS-20-006

Funding Opportunity Purpose

A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system. This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models, are outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.

White Matter Lesion Etiology of Dementia in the U.S. Including in Health Disparity Populations (U19 Clinical Trial not Allowed)

RFA
Monday, December 30, 2019
Wednesday, April 1, 2020
U19
RFA-NS-20-013

Funding Opportunity Purpose

Despite established associations between white matter lesions and cognitive impairment including dementia, the volume, anatomical location, and other key cellular and molecular characteristics of white matter lesions that are both necessary and sufficient are unknown, as are the comorbid clinical factors that may modify (including protect from) these effects. Therefore, this initiative will support one large prospective clinical research study in the U.S. studying individuals with white matter lesions at risk for cognitive decline to determine the magnitude and anatomical locations that are both necessary and sufficient to cause cognitive impairment and dementia. The study will include health disparities populations, and will examine additional clinical factors and comorbidities that may be effect modifiers of the relationship between white matter lesions and cognitive impairment, including dementia. Clinical trial-ready VCID biomarkers should be utilized, further developed, and/or subject to implementation research in this study. Secondary goals include: identifying clinical and mechanistic targets for future VCID interventional trials; determining interrelationships (cross-sectional and longitudinal) among white matter lesions, cerebro- and cardio-vascular disease and risk factors including dementia-relevant genes. Applicants are encouraged, when scientifically advantageous, to utilize existing resources for VCID and stroke research, e.g. MarkVCID, StrokeNet, Alzheimers Centers, and large NIH funded prospective cohort studies (e.g. Framingham, ARIC, CHS, NOMAS, etc.) as well as other dementia resources.

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

PAS
Thursday, July 18, 2019
Translational Research, Clinical Trials Research
Wednesday, September 7, 2022
R41/R42
PAS-19-317

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications to NIA's Small Business Technology Transfer Research (STTR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

PAS
Thursday, July 18, 2019
Translational Research, Clinical Trials Research
Wednesday, September 7, 2022
R43/R44
PAS-19-316

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications to NIA's Small Business Innovation Research (SBIR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

PAR
Wednesday, May 8, 2019
Sunday, May 8, 2022
R03
PAR-19-276

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed

PA
Tuesday, May 7, 2019
Tuesday, April 7, 2020
R43/R44
PA-19-272

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01 Clinical Trial Not Allowed)

RFA
Monday, April 8, 2019
Thursday, October 1, 2020
R01
RFA-MH-20-135

Funding Opportunity Purpose

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.no

Institutional Translational Research Training Program (T32)

PAR
Friday, March 22, 2019
Thursday, May 27, 2021
T32
PAR-19-228

Funding Opportunity Purpose

The purpose of the NINDS Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic neuroscientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS mission, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies.

Pages